Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
- 24 March 2005
- Vol. 330 (7493) , 716-720
- https://doi.org/10.1136/bmj.330.7493.716
Abstract
Monoclonal antibodies and fusion proteins have become an important group of drugs (known as biologic drugs) for treatment of chronic autoimmune disorders.w1 Advances in antibody engineering and new techniques have allowed the generation of fusion proteins and chimeric, humanised, and fully humanised monoclonal antibodies. Fourteen biologic drugs have already been approved in the United States (by the US Food and Drug Administration (FDA)) and in other countries; over 70 are in late stage clinical trials (at least phase II) and over 1000 in preclinical development.w2Keywords
This publication has 27 references indexed in Scilit:
- Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004Annals of the Rheumatic Diseases, 2004
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answerArthritis & Rheumatism, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnnals of the Rheumatic Diseases, 2004
- Protective strategies against ischemic injury of the liverGastroenterology, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002